All articles tagged with #antigen composition
The WHO's TAG-CO-VAC recommends updating COVID-19 vaccine antigens to monovalent LP.8.1 to better target circulating SARS-CoV-2 variants, while noting that existing JN.1 lineage vaccines remain suitable. Ongoing surveillance and data collection are emphasized to adapt vaccine strategies as the virus evolves.
The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has recommended retaining the current COVID-19 vaccine antigen composition, specifically a monovalent XBB.1.5, due to the broad immune responses demonstrated against circulating variants. The group advises further data collection on immune responses and vaccine effectiveness, as well as strengthened surveillance to monitor the antigenic distinctness of emerging variants. The TAG-CO-VAC also encourages the development of vaccines that can improve protection against infection and reduce transmission of SARS-CoV-2.
The WHO Technical Advisory Group on COVID-19 Vaccine Composition has recommended updates to COVID-19 vaccine antigen composition to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants, particularly against symptomatic disease. The group advises moving away from the inclusion of the index virus in future formulations of COVID-19 vaccines. The recommendations are based on the genetic and antigenic evolution of SARS-CoV-2, the performance of currently approved vaccines against circulating SARS-CoV-2 variants, and the need for continued monitoring of the evolution of SARS-CoV-2.